Posts tagged vaccine
Ladenburg up Novavax to buy

Ladenburg Thalmann upgraded Novavax (NASDAQ:NVAX) to “buy” from “neutral” with a new price target of $1.60 after the company presented encouraging preclinical data from its nanoparticle influenza vaccine, NanoFlu, and outlined a clinical development strategy targeting older adults. The stock closed at 97 cents on Aug. 8.

Read More
Maxim cuts Stellar price target to $4

Maxim Group reduced its price target for Stellar Biotechnologies (NASDAQ:SBOT) to $4 from $7, saying demand for the company’s keyhole limpet hemocyanin (KLH) is a slow climb. The stock was quoted at $2.59 at midday Dec 2.

Read More
Turnstone Biologics in $41.4-million financing

Closely-held Turnstone Biologics has completed a $41.4-million series B financing led by new investor, OrbiMed, with participation from another new investor, F-Prime Capital Partners, and existing investors, FACIT and Versant Ventures, which led Turnstone’s series A financing. 

The series B financing takes place less than a year from the series A that allowed the company to progress its lead asset through an initial Phase 1/2 trial to establish safety, maximum tolerated dose and initial evidence of immunological activity in patients with advanced solid and metastatic tumors. 

Read More
Roth starts Heat Biologics at buy

Roth Capital Partners has initiated coverage of Heat Biologics (NASDAQ:HTBX) with a “buy” rating and $2.75 price target. The stock closed at 60 cents on Friday.

“Heat Biologics possesses a portfolio of unique, differentiated vaccines that, in our opinion, could bring a much needed boost to the cancer vaccine space, which has been plagued by recent failures,” writes analyst Joseph Pantginis.

Read More